Novo Nordisk Healthcare Ag

Novo Nordisk A/s

Susanne Bang

Jing Su

Lars Thim

Allan Christian Shaw

Nils Langeland Johansen

Kjeld Madsen

Niels Christian Kaarsholm

Arne Staby

Janus Krarup

Haleh Ahmadian

Are Bogsnes

Thomas Budde Hansen

Daniel E Rasmussen

Peter Thygesen

Anne Charlotte Arentsen

Birgitte Koch Michelsen

Anette Sams Nielsen

Johan Karlsson

The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides.

Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest

The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.

Basic protein purification tags from thermophilic bacteria

A method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part is described. The invention is advantageous in that it is a single step chromatographic process which does not require adjustment of pH or conductivity during loading step and results in high yield and potency. The process is used for the purification of recombinant compositions of coagulation factor, particularly recombinant Factor VIII.

Purification of factor VIII using a mixed-mode or multimodal resin

The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.

Purification of factor XIII polypeptides from biological materials

The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

GLP-2 compounds, formulations, and uses thereof

Growing community of inventors

Bagsvaerd, Denmark

Susanne Bang